Dashboard
Manage Tickers

MBRXMoleculin Biotech, Inc.

Nasdaq moleculin.com


$ 4.88 $ -0.02 (-0.42 %)    

Friday, 10-May-2024 11:39:11 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 4.76
$ 4.88
$ 0.00 x 0
$ 0.00 x 0
$ 4.88 - $ 4.88
$ 4.28 - $ 15.75
41,273
na
11M
$ 1.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-22-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 03-24-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-16-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 02-21-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-10-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-28-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 04-03-2017 12-31-2016 10-K
31 11-21-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 06-16-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

moleculin-biotech-q1-eps-202-beats-353-estimate
Moleculin Biotech Q1 EPS $(2.02) Beats $(3...
05/10/2024 21:09:42

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3...

moleculin-biotech-received-issue-notification-from-us-patent-and-trademark-office-for-us-patent-number-11980634-titled-method-of-reconstituting-liposomal-annamycin
Moleculin Biotech Received Issue Notificat...
05/09/2024 12:43:26

Patent, once issued, will provide composition protection through 2040, with potential for additional term extensionAnnamycin is...

moleculin-reports-higher-aml-complete-remission-rates-and-durability-with-additional-interim-subject-data
Moleculin Reports Higher AML Complete Remi...
05/07/2024 13:02:30

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)Ful...

moleculin-announces-formation-of-scientific-advisory-board-to-support-development-of-annamycin
Moleculin Announces Formation Of Scientifi...
05/01/2024 13:01:27

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
04/26/2024 12:06:32

european-medicines-agency-grants-orphan-drug-designation-for-moleculins-treatment-of-acute-myeloid-leukemia
European Medicines Agency Grants Orphan Dr...
04/18/2024 12:36:14

roth-mkm-maintains-buy-on-moleculin-biotech-maintains-40-price-target
Roth MKM Maintains Buy on Moleculin Biotec...
04/12/2024 16:24:03

Roth MKM analyst Jonathan Aschoff maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $40 price target.

moleculin-presents-data-for-anthracycline
Moleculin Presents Data For Anthracycline
04/10/2024 12:34:09

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
04/08/2024 20:31:20

moleculin-received-us-patent-issue-notification-for-annamycin-targeting-unmet-need-in-aml
Moleculin Received U.S. Patent Issue Notif...
03/27/2024 13:06:48

maxim-group-maintains-buy-on-moleculin-biotech-lowers-price-target-to-20
Maxim Group Maintains Buy on Moleculin Bio...
03/26/2024 13:24:15

Maxim Group analyst Jason McCarthy maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $45...

moleculin-biotech-provided-a-preliminary-update-on-recent-clinical-activity-and-expected-near-term-milestones-for-its-lead-program-mb-106-for-the-treatment-of-acute-myeloid-leukemia
Moleculin Biotech Provided A Preliminary U...
03/25/2024 11:36:34

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects AnnAraC has po...

moleculin-biotech-fy23-eps-1507-vs-1522-yoy-as-of-december-31-2023-the-company-had-cash-and-cash-equivalents-of-236m
Moleculin Biotech FY23 EPS $(15.07) Vs $(1...
03/22/2024 20:10:32

Summary of Financial Results for the Full Year 2023Research and development (R&D) expenses were $19.5 million and $19.0 mil...

trading-halt-halt-status-updated-at-85500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:55:...
03/22/2024 12:55:04

earnings-scheduled-for-march-22-2024
Earnings Scheduled For March 22, 2024
03/22/2024 09:40:22

Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share o...

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
03/21/2024 23:50:04

a-preview-of-moleculin-biotechs-earnings
A Preview Of Moleculin Biotech's Earnings
03/21/2024 14:00:50

micron-signet-jewelers-and-3-stocks-to-watch-heading-into-wednesday
Micron, Signet Jewelers And 3 Stocks To Wa...
03/20/2024 06:44:55

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as f...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/19/2024 21:34:06

moleculin-announces-1-for-15-reverse-stock-split
Moleculin Announces 1-For-15 Reverse Stock...
03/19/2024 20:32:52

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION